The estimated prevalence of the Chronic Obstructive Pulmonary Disease (COPD) in Spain is 10.2% in population aged 40-80 years old. 1 More than 3 million people died worldwide in 2015 due to COPD. 2 The main objective of this study was to estimate the economic impact of COPD on society and the quality of life of patients in the Spanish region of Extremadura in 2015. Extremadura is a region with a relatively old population and a low population density, which makes it an optimal place for the development of this study as a pilot experience for future analysis in other regions. The average annual cost for a COPD patient was €3,757.3 (95% confidence interval: €3,077 -€4,438). Figure 1 shows the distribution of total annual costs by type of cost.
INTRODUCTION
The estimated prevalence of the Chronic Obstructive Pulmonary Disease (COPD) in Spain is 10 .2% in population aged 40-80 years old. 1 More than 3 million people died worldwide in 2015 due to COPD. 2 The main objective of this study was to estimate the economic impact of COPD on society and the quality of life of patients in the Spanish region of Extremadura in 2015. Extremadura is a region with a relatively old population and a low population density, which makes it an optimal place for the development of this study as a pilot experience for future analysis in other regions. The average annual cost for a COPD patient was €3,757.3 (95% confidence interval: €3,077 -€4,438). Figure 1 shows the distribution of total annual costs by type of cost.
Medication is the largest DHC (€731. Data on demographic characteristics were collected, as well as retrospective healthcare, non-healthcare resource utilization, and labour productivity losses for the last 12 months from medical records and investigator-administered electronic questionnaires. We used a 1-year prevalence approach and a bottom-up costing method to estimate average annual costs per patient, using 2015 as the base year, from a societal perspective. 3 Costs only consider the resource consumption due to COPD.
Direct healthcare costs (DHC):
• The cost of medication related to respiratory disease was obtained from medical records.
• The costs of healthcare visits, tests, emergency services and home oxygen therapy were calculated by multiplying resource quantities by the average of official unit costs. 4 • Hospitalization costs were obtained by their main Diagnosis-Related Group (DRG). 5
Direct non-healthcare costs (DNHC):
• The costs of informal care, defined as the time used in performing tasks that help maintain or enhance the patient´s health, were calculated by the proxy good method. 6 This cost was considered equivalent to the minimum wage of a domestic employee who works for hours (because of non-specialized care), multiplied by the hours of informal care received.
• The costs of nursing homes, attendance to day care centres and professional caregiving, due to COPD, were calculated by multiplying resource quantities by their unit costs.
Indirect costs (IC):
• IC included labour productivity losses of the patient, i.e. the cost derived from absenteeism in employees, early retirement and unemployment when, according to the patient's perception, the situation was directly related to COPD. Losses were measured through the human capital method, that is, as the wage lost or not earned by the patient as a result of the illness, calculated by the imputation of the average wage that a person receives in a day.
Total costs are the sum of DHC, DNHC and IC. Results were analysed by COPD severity, gender and age group.
METHODS
A total of 386 patients with COPD were included in the study. Table 1 shows patient characteristics.
RESULTS
The two main limitations of our study are: first, we haven't consider the intangible costs associated to COPD; second, we found a high rate of patients with unknown information about their COPD severity.
LIMITATIONS
DHC and DNHC showed differences (p<0.05) by severity group and by age group: lower severity of COPD and lower age (<65 years old) are associated to lower costs, compared to higher severity of COPD and higher age (≥65 years old). Age group showed differences (p<0.05) related to IC, with higher costs in <65 years old group. Gender was not a significant variable in any type of cost.
Higher total costs were associated to higher severity of COPD and lower age, as patients under 65 have higher IC, which compensate their lower DHC and DNHC.
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CONCLUSIONS
This is the first study that estimate, through a bottom-up approach in a representative sample of adult population, costs associated to COPD from a societal perspective.
COPD is a important burden for the healthcare system and for the whole society.
Related to the distribution of DHC, our results show a higher proportion of medication (44.5%) and a lower proportion of hospitalization (23.1%) than other studies (35%-40% and 40%-45% respectively). [8] [9] [10] [11] Results also show the high labour incapacity related to COPD, as IC represent 17.9% of total costs. Moreover, its high underdiagnosis could underestimate the socioeconomic impact of the disease. As advance stage of disease is associated to higher costs, preventive measures could substantially reduce both economic and social impact. 
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